Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • GSK Pharma Q4 net...

    GSK Pharma Q4 net profit rises 16.56 percent to Rs 123 crore

    GarimaWritten by Garima Published On 2019-05-21T09:30:42+05:30  |  Updated On 17 Aug 2021 11:43 AM IST

    The company had posted a net profit of Rs 105.55 crore for the corresponding period of the previous fiscal, GSK said in a filing to the BSE.


    New Delhi: Drug firm Glaxo Smith Kline Pharmaceuticals Monday reported a 16.56 per cent rise in its standalone net profit to Rs 123.03 crore for the quarter ended March 31.


    The company had posted a net profit of Rs 105.55 crore for the corresponding period of the previous fiscal, GlaxoSmithKline Pharmaceuticals said in a filing to the BSE.


    Read Also: GSK Consumer Healthcare Q4 profit up 35 percent to Rs 285 crore







    Its standalone revenue from operations stood at Rs 751.22 crore for the quarter under consideration. It was Rs 748.62 crore for the corresponding quarter a year ago.








    For the fiscal year ended March this year, the company posted a net profit of Rs 425.36 crore as against Rs 351.98 crore for the previous fiscal year.


    Standalone revenue from operations for the fiscal year ended March 2019 stood at Rs 3,128.53 crore. It was Rs 2,895.88 crore for the year-ago fiscal.


    Read Also: Patent Infringement: Vectura wins case against GSK; awarded $89.7 million in damages

    The company said its board has recommended a dividend of Rs 20 per equity share on a face value of Rs 10 each for the year ended March 31.


    Shares of Glaxo Smith Kline Pharmaceuticals were trading at Rs 1,280 per scrip on the BSE, up 0.66 per cent from its previous close.

    BSEdividendDrug firm Glaxo Smith Kline PharmaceuticalsFinancial resultsfinancial yearfiscal yearfourth quarterFY marchGlaxo Smith KlineGSKGSK PharmaGSK PharmaceuticalsGSK profitGSK Q4Q4Shares of Glaxo Smith Kline Pharmaceuticalsstandalone
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok